Paul Nouri, CFP
Hedge fund manager, long/short equity, healthcare

MGC Diagnostics Overhaul Should Reward Investors Over Next 12 Months

Over the past ten years, MGC Diagnostics (NASDAQ:MGCD) has given investors little reason to cheer, with uneven revenue growth and no cumulative net income. All of that may be about to change. As you can see in the two charts below, movements in the stock have had a long term correlation with sales growth. If new management can consistently drive sales higher, which we think it can, shares should follow.

(click to enlarge)

(click to enlarge)


MGC Diagnostics' product line consists of a series of devices that test the cardiorespiratory functions of patients. Early detection of cardiac and pulmonary issues can end up saving healthcare systems more money down the line. For this reason, we don't see...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details